<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662724</url>
  </required_header>
  <id_info>
    <org_study_id>7972_BO_K_2018</org_study_id>
    <nct_id>NCT03662724</nct_id>
  </id_info>
  <brief_title>Venetoclax Registry</brief_title>
  <acronym>VENreg</acronym>
  <official_title>Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in
      the Treatment of Acute Myeloid Leukemia With Venetoclax
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to document all patients with AML who are treated with the BCL2
      inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry
      study in a standardised manner. Data is collected retrospectively and multi-centric. It is
      neither a therapy study nor is the therapy influenced by this study.

        1. Systematic and uniform collection and documentation of all patients treated with the
           BCL2 inhibitor Venetoclax.

        2. Collection and integrative analysis of clinical data of included patients.

        3. Mutation analysis of available patient samples and correlation with clinical parameters.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall response rate of Venetoclax treatment.</measure>
    <time_frame>4 months</time_frame>
    <description>Overall response rate of Venetoclax treatment (complete remission, complete remission with incomplete regeneration, partial remission)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival during Venetoclax treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Event-free survival of patients with relapsed/refractory AML receiving Venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival during Venetoclax treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse-free survival of patients with relapsed/refractory AML receiving Venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival during Venetoclax treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival of patients with relapsed/refractory AML receiving Venetoclax</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.</description>
    <other_name>Venclyxto</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA (either bone marrow or peripheral blood)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patiens with relapsed/refractory AML including patients who received stem cell
        transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        relapsed/refractory AML

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Heuser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rabia Shahswar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gernot Beutel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/refractory adult acute myeloid leukemia (AML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

